Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TOPIC

Financiado

Cerrado

TOPIC Targeting Cytotoxic Protein Oligomers

"Parkinson's disease and Huntington's disease are highly debilitating diseases for which no disease modifying treatment is available. This EID proposal, called TOPIC (Targeting Cytotoxic Protein Oligomers), will train 2 ESRs to ta... ver más

31/08/2017

586K€

Presupuesto del proyecto: 586K€

Líder del proyecto

AARHUS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-08-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

0.00€ | Lider

CBB

32.24K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

NOVEL TOOLS IN PD Novel tools for real time monitoring and quantification of p... 1M€ Cerrado

SUPD Sizing Up PD Cavity enhanced Characterisation of Single Bio... 290K€ Cerrado

Oligomers Characterising protein oligomers and their role in neurodege... 2M€ Cerrado

PROTEASOME-AMYLOID Linking aggregation of alpha synuclein to proteasomal dysfun... 173K€ Cerrado

SAF2009-07600 ESTUDIO DEL PROCESO DE AGREGACION DE LA PROTEINA B-AMILOIDE... 175K€ Cerrado

PD-MitoQUANT PD MitoQUANT A quantitative approach towards the character... 7M€ Cerrado

Líder del proyecto

AARHUS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 586K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "Parkinson's disease and Huntington's disease are highly debilitating diseases for which no disease modifying treatment is available. This EID proposal, called TOPIC (Targeting Cytotoxic Protein Oligomers), will train 2 ESRs to target the oligomeric protein aggregate which accumulates in these diseases. These oligomers occur under conditions which eventually lead to the accumulation of fibrillar amyloid deposits. However, there is increasing consensus that the amyloid state is biologically inert and the cytotoxic species is the oligomeric structure. Our approach rests on the working hypothesis that the cytotoxic oligomers engage in a number of unwanted interactions with proteins and membranes. The 2 ESRs will combine proprietary technology to stabilize these oligomers with state-of-the-art mass spectrometry and biophysical techniques to identify, quantitate and rank these interactions within the context of the cellular interactome. The next goal (building directly on the EID outcome but outside its present scope) is to develop small-molecule inhibitors of these interactions as a therapeutic strategy to eliminate cell death and disease progression. This training programme offers a unique opportunity for the 2 ESRs to carry out central parts of translational research in both an academic and SME setting, spanning a multitude of different cellular, biophysical and mass spectrometric techniques of general use in the life sciences. Our target oligomeric proteins are α-synuclein (Parkinson’s Disease) and the N-terminal part of exon 1 of huntingtin (Huntington’s Disease). By analysing two different proteins in parallel projects, we will be able to validate the robustness of our approach and potentially identify generic small molecules to target misfolded protein oligomers in general. Our approach will allow the ESRs to develop a general therapeutic strategy that targets a major class of devastating disease affecting the daily lives of millions of people throughout the world."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores